The Journal

Your Cholesterol Looks Fine. What Else Matters for Heart Risk?

By Ilya Rabkin, MD, MBA ·

Quick Takeaway

  • A standard cholesterol panel is useful, but a result that isn’t flagged doesn’t automatically mean your cardiovascular risk is low.
  • Family history can change how I interpret otherwise reassuring numbers.
  • The 2026 cholesterol guidelines recommend checking lipoprotein(a), or Lp(a), at least once in adulthood. ApoB and selected particle testing can add useful information in some people.
  • A persistently elevated hs-CRP can add to cardiovascular risk assessment. Homocysteine is more complicated and is not a primary cardiovascular treatment target.
  • A coronary calcium scan measures calcified plaque. A score of zero is reassuring in the right patient, but it does not prove there is no noncalcified plaque.

“My Cholesterol Is Normal. Am I Good?”

I hear some version of this fairly often.

Someone exercises, eats reasonably well, doesn’t smoke, and gets a lipid panel back without any red numbers. LDL isn’t dramatically elevated. HDL may look good. Triglycerides may be normal.

So how much reassurance should they take from that?

A standard lipid panel is still an important starting point, and LDL cholesterol remains one of the major cardiovascular risk factors we can change. But I wouldn’t use one normal-looking panel as a complete heart-risk assessment.

The 2026 ACC/AHA dyslipidemia guideline takes a broader approach. LDL is still central, but overall risk, family history, selected additional blood tests, and coronary artery calcium imaging can help when they might actually change a decision.1

Start With the Basics

Before I order anything “advanced,” I want the ordinary information.

Blood pressure matters. So do smoking, diabetes, kidney disease, age, metabolic health, physical activity, and family history. The new guideline uses the PREVENT equations in adults ages 30 to 79 without known cardiovascular disease to estimate 10- and 30-year risk.1

The same LDL can mean something different in two different people. An LDL of 125 mg/dL in a healthy 35-year-old is a different conversation from the same LDL in someone with diabetes, kidney disease, or a parent who had a heart attack at 48.

The “normal range” printed beside a lab result also isn’t necessarily the right target for an individual patient.

Family History Can Change the Conversation

Did a parent or sibling have a heart attack, stroke, bypass surgery, or coronary stent unusually young?

The 2026 guideline considers premature cardiovascular disease in a parent or sibling a risk-enhancing factor, generally meaning before age 55 in men or 65 in women.1

That is different from a grandparent having a heart attack at 86. A strong family history can make otherwise reassuring cholesterol numbers less reassuring. It is also one reason Lp(a) has become more important.

Lp(a): A Test Most Adults Should Probably Have Once

Lipoprotein(a), shortened to Lp(a), is a cholesterol-carrying particle that is largely determined by genetics. You can eat well, exercise regularly, and still have a high Lp(a). Lifestyle usually doesn’t change it very much.2

The 2026 guideline recommends measuring Lp(a) at least once in adulthood. A level of 125 nmol/L or 50 mg/dL and above is considered a risk-enhancing level, with risk increasing further at higher concentrations.1

If I find a high Lp(a), I’m usually using that information to decide how aggressively we should manage the things we can change: LDL cholesterol, blood pressure, diabetes risk, smoking, activity, and the rest of the cardiovascular picture.

A very high result can also be useful information for relatives because Lp(a) tends to run in families.2

ApoB and the Question of Particle Number

ApoB has become popular in longevity medicine and on podcasts, sometimes with the claim that LDL cholesterol is outdated and ApoB is the only number that matters.

I wouldn’t go that far, but ApoB is genuinely useful.

Most particles that can enter the artery wall and contribute to plaque carry one ApoB molecule. ApoB therefore gives us an estimate of the number of atherogenic particles in circulation, while LDL cholesterol tells us how much cholesterol is being carried inside many of those particles.

Usually those measurements move together. Sometimes they don’t.

A 2025 systematic review found that ApoB predicted cardiovascular risk better than LDL cholesterol when the measures disagreed.3 The 2026 guideline recommends ApoB selectively, particularly with elevated triglycerides, diabetes, or situations where LDL may underestimate particle-related risk.1

What About Particle Size and an “Advanced Lipid Panel”?

I do sometimes order more detailed lipid testing that includes LDL particle number, particle size, and the distribution of different lipoprotein particles.

It doesn’t change what I do in every patient, but sometimes it adds useful context. A standard panel may look only mildly abnormal while the advanced panel shows more LDL particles or a greater proportion of smaller, denser particles. That can be helpful when the rest of the picture suggests insulin resistance, elevated triglycerides, or other metabolic risk.

A systematic review and meta-analysis found that higher LDL particle number and smaller LDL particle size were associated with higher cardiovascular risk.4

I wouldn’t treat particle size as an isolated target. Particle number and ApoB generally have stronger clinical utility, and the 2026 guideline notes that most advanced lipoprotein measurements do not routinely improve risk classification beyond a standard lipid panel plus ApoB and Lp(a). It recommends using advanced testing when the information is likely to meaningfully change the treatment plan.1

That is close to how I use it. Sometimes it confirms what we already suspected. Occasionally it pushes me toward earlier or more aggressive intervention. Sometimes it simply gives us more information without changing the plan.

What About Inflammation?

One marker I sometimes use is high-sensitivity C-reactive protein, or hs-CRP. It is an inflammatory marker rather than a cholesterol measurement.

The 2026 guideline considers an hs-CRP of 2 mg/L or higher on more than one occasion a cardiovascular risk enhancer when it is measured.1 The repeat measurement matters because CRP can rise with an infection, injury, or other temporary inflammation.

A persistently elevated hs-CRP can add useful information when the rest of the risk picture is borderline.

And homocysteine?

Homocysteine is different, and I don’t put it in the same category as hs-CRP.

Higher levels have been associated with vascular risk, and I sometimes find it useful as part of a broader metabolic or nutritional evaluation. But lowering the homocysteine number has not consistently translated into fewer cardiovascular events.

A Cochrane review found that folate and B-vitamin treatment did not reduce heart attacks or overall mortality, although there was a small reduction in stroke.5 If homocysteine is elevated, I want to understand why rather than assume that lowering the number itself will prevent a heart attack.

When a Calcium Scan Can Actually Help

Sometimes the blood work is done and the decision is still not obvious.

A coronary artery calcium, or CAC, scan can be useful when someone is unsure about starting lipid-lowering medication or when estimated risk leaves us in a gray area.

It is a quick, noncontrast CT scan that measures calcified plaque in the coronary arteries. The 2026 guideline supports CAC scoring in selected men age 40 and older and women age 45 and older when it would help clarify risk or guide treatment.1

A higher calcium burden means we already have visible evidence of coronary atherosclerosis and usually pushes the prevention conversation in a more aggressive direction.

A score of zero can be reassuring, but there is an important limitation: a calcium score only detects plaque that has calcified.

Coronary arteries can also contain noncalcified plaque, often called “soft plaque,” and that does not show up on a standard calcium score. A 2024 systematic review and meta-analysis of more than 37,000 asymptomatic people with CAC zero found that about 10% still had some noncalcified coronary plaque on coronary CT angiography. Obstructive noncalcified disease was uncommon, at about 1%.6

So CAC zero does not mean “zero plaque” or “zero risk.” It remains a useful risk marker when used in the right patient.

Coronary CT angiography, or CCTA, can visualize both calcified and noncalcified plaque, but it is a different test with different indications. I don’t think everyone with a zero calcium score needs a CCTA.

What Would Actually Change?

This is the question I care about most before ordering an advanced test.

A high Lp(a) may make me more aggressive about LDL and other modifiable risks. A high ApoB or LDL particle number may show that a decent-looking LDL cholesterol is underestimating the number of atherogenic particles in circulation. Particle size may add context to the metabolic picture. A persistently elevated hs-CRP can add another piece to a borderline risk assessment.

A positive calcium scan can make the case for lipid-lowering treatment much clearer. A score of zero may help some lower-risk patients make a more individualized decision when the benefit of starting medication is less certain.

And sometimes, after looking at everything, the answer is that someone is already doing well and doesn’t need another test or another medication.

I like advanced testing when I know what I’m going to do with the answer. Ordering every available cardiovascular biomarker simply because it exists is less useful.

Where I Land

A cholesterol panel that looks good is good news. I just wouldn’t let it end the cardiovascular prevention conversation automatically.

For most people, the biggest gains still come from familiar things: not smoking, controlling blood pressure, staying active, maintaining metabolic health, and managing LDL appropriately for their level of risk.

We also have additional tools that can be useful when they answer a real clinical question. I think Lp(a) deserves a one-time check in most adults. ApoB is useful when the standard lipid panel may not tell the whole story. I sometimes use more detailed particle testing when it could clarify an otherwise moderate or discordant picture. hs-CRP can add information about inflammatory risk. A coronary calcium scan can be very helpful when the treatment decision is genuinely uncertain.

I want enough information to make a better prevention decision for the person sitting in front of me, without turning prevention into an endless search for more numbers.

References

  1. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. doi:10.1161/CIR.0000000000001423.
  2. Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925-3946. doi:10.1093/eurheartj/ehac361.
  3. Sehayek D, Cole J, Björnson E, et al. ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. J Clin Lipidol. 2025;19(4):844-859. doi:10.1016/j.jacl.2025.05.024.
  4. Quesada JA, Bertomeu-González V, Orozco-Beltrán D, et al. The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk prediction: a systematic review and meta-analysis. Clin Investig Arterioscler. 2023;35(4):165-177. doi:10.1016/j.arteri.2022.11.001.
  5. Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8(8):CD006612. doi:10.1002/14651858.CD006612.pub5.
  6. Sama C, Abdelhaleem A, Velu D, et al. Non-calcified plaque in asymptomatic patients with zero coronary artery calcium score: a systematic review and meta-analysis. J Cardiovasc Comput Tomogr. 2024;18(1):43-49. doi:10.1016/j.jcct.2023.10.002.

Medical Disclaimer

This article is for educational purposes and does not provide individualized medical advice, diagnosis, or treatment. Cardiovascular risk assessment and decisions about laboratory testing, imaging, lifestyle changes, or medication should be individualized based on medical history, family history, examination findings, and overall cardiovascular risk.

Editorial Disclosure

This article was written by Ilya Rabkin, MD, MBA, with AI-assisted research organization, reference checking, and editorial support. All clinical interpretations, recommendations, and references were reviewed by Dr. Rabkin before publication.

← Back to The Journal